ezetimibe + atorvastatin

**Yilituo** is a branded, oral fixed-dose lipid-lowering combination of **ezetimibe** and **atorvastatin calcium**. The Yilituo II tablet used as the reference product in the supplied bioequivalence context contains ezetimibe 10 mg plus atorvastatin 20 mg. Ezetimibe inhibits intestinal cholesterol absorption through Niemann-Pick C1-like protein 1, while atorvastatin competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase and reduces hepatic cholesterol synthesis. The complementary mechanisms lower low-density-lipoprotein cholesterol and are approved for hypercholesterolemia, including homozygous familial hypercholesterolemia. ([drugs.dxy.cn](https://drugs.dxy.cn/pc/drug/brtTp0mepepmplspls9FUrXdQIGFGj4Q%3D%3D?ky=%E9%98%BF%E6%89%98%E4%BC%90%E4%BB%96%E6%B1%80))

Brand names

AtozetKexroltLiptruzetLypqozetOrvatezTioblisYilituo益立妥

Other names

atorvastatin + ezetimibeatorvastatin and ezetimibeezetimibe + atorvastatinezetimibe and atorvastatinezetimibe and atorvastatin calciumezetimibe and atorvastatin calcium tabletsezetimibe/atorvastatin依折麦布阿托伐他汀钙片